- The first wave: HCV NS3 protease inhibitors telaprevir and boceprevirKristen M Marks
Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
Antivir Ther 17:1119-31. 2012..This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions...
- Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapyKristen M Marks
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 52:595-9. 2009..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV...
- Identification of substance use and dependence among patients with viral hepatitisColin B Jackson
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA
Dig Liver Dis 42:650-6. 2010..As drug abuse and addiction have been shown to decrease adherence to treatment of hepatitis C virus (HCV) or HIV, screening for substance use should be standard clinical practice in those undergoing an evaluation for these diseases...
- Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 192:1943-9. 2005..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized...